JP2005272456A - Hypoglycemic agent or cathartic agent - Google Patents

Hypoglycemic agent or cathartic agent Download PDF

Info

Publication number
JP2005272456A
JP2005272456A JP2005048803A JP2005048803A JP2005272456A JP 2005272456 A JP2005272456 A JP 2005272456A JP 2005048803 A JP2005048803 A JP 2005048803A JP 2005048803 A JP2005048803 A JP 2005048803A JP 2005272456 A JP2005272456 A JP 2005272456A
Authority
JP
Japan
Prior art keywords
albedo
agent
grapefruit
hypoglycemic
food
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2005048803A
Other languages
Japanese (ja)
Inventor
Kazunari Mizobata
和成 溝端
Fumiko Yamauchi
文子 山内
Noriyuki Miyazaki
敬之 宮崎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takara Shuzo Co Ltd
Original Assignee
Takara Shuzo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takara Shuzo Co Ltd filed Critical Takara Shuzo Co Ltd
Priority to JP2005048803A priority Critical patent/JP2005272456A/en
Publication of JP2005272456A publication Critical patent/JP2005272456A/en
Pending legal-status Critical Current

Links

Abstract

<P>PROBLEM TO BE SOLVED: To provide a hypoglycemic agent capable of being ingested in a large amount at one time, excellent in safety, and having higher efficacy than ever, and to provide a cathartic agent. <P>SOLUTION: This hypoglycemic agent contains albedo of citrus fruits as an active ingredient. A hypoglycemic food or beverage contains the hypoglycemic agent. The cathartic agent contains the albedo of the citrus fruits as an active ingredient. A cathartic food or beverage contains the cathartic agent. A representative example of the citrus fruits containing the albedo is grapefruit. The albedo may be processed in such a degree that its pharmacological effect is not inhibited. The albedo used herein is given at a reduced cost and scarcely has a side effect. <P>COPYRIGHT: (C)2006,JPO&NCIPI

Description

本発明は、柑橘類由来の血糖値降下剤、便通改善剤に関する。   The present invention relates to a citrus-derived hypoglycemic agent and a bowel movement improving agent.

成人病と呼ばれていた生活習慣病は、年齢に関係なく子供を含めたほとんどの日本人に発病する可能性があり、近年、生活習慣病患者や予備軍が著しく増加しており、大きな社会問題となっている。
生活習慣病は、食習慣、運動習慣、休養、喫煙、飲酒等の生活習慣が、その発症や進行に大きく関与する慢性の病気のことであり、糖尿病、肥満、高脂血症、高尿酸血症、循環器疾患、大腸癌、高血圧症、肺扁平上皮癌、慢性気管支炎、肺気腫、アルコール性肝障害、歯周病などが含まれる。
中でも生活習慣病の代表である糖尿病の患者は近年急増しており、現在日本では、程度の差はあれ中高年の10人に1人が糖尿病であるともいわれている。糖尿病は、血液中のブドウ糖の値(血糖値)がある基準を越えて高くなる病気であり、血糖値が高い状態が長い間続くと、血管壁が傷つき、様々な血管の合併症に伴う全身の臓器の合併症が起こってくる。糖尿病の治療の基本は、食事療法や運動療法などによって血糖をコントロールすることであり、特に食事療法は重要である。そこで一般家庭においては、生活習慣病予防のために食習慣を改善する様々な取組みがなされており、より安全性に優れた生活習慣病予防作用を有する飲食品の開発が望まれている。
Lifestyle-related illnesses called adult illnesses can occur in almost all Japanese people, including children, regardless of age. In recent years, the number of lifestyle-related disease patients and the reserve army has increased remarkably. It is a problem.
Lifestyle-related diseases are chronic diseases in which lifestyle habits such as eating habits, exercise habits, rest, smoking, and drinking are greatly involved in the onset and progression of diabetes, obesity, hyperlipidemia, hyperuricemia Disease, cardiovascular disease, colon cancer, hypertension, squamous cell lung cancer, chronic bronchitis, emphysema, alcoholic liver disorder, periodontal disease and the like.
Among them, the number of diabetic patients, who are representative of lifestyle-related diseases, has been increasing rapidly in recent years. In Japan, it is said that one out of 10 middle-aged and older people has diabetes. Diabetes mellitus is a disease in which the level of glucose in the blood (blood glucose level) rises above a certain level. If the state of high blood glucose level continues for a long time, the blood vessel wall is damaged and the whole body associated with various vascular complications. Complications of the organs occur. The basis of treatment of diabetes is to control blood sugar by diet therapy or exercise therapy, and diet therapy is particularly important. Therefore, various efforts have been made to improve eating habits in order to prevent lifestyle-related diseases in general households, and it is desired to develop foods and drinks having a lifestyle-safety-preventing action that is superior in safety.

一方、食品の機能については、食品の栄養素による生命維持の機能(一次機能)、食品の成分が生体感覚に訴える機能(二次機能)、体調調節を行う機能(三次機能)がある。食品の栄養(一次機能)、味覚(二次機能)については、十分解明され、認識されているが、近年、食品の持つ生体防御、体調リズム調節、疾病予防及び回復といった三次機能が注目されている。食品は、毎日一生食べ続けるものであり、体に対して長期にわたる影響を及ぼす可能性が大きく、食品の機能性に関して多くの研究開発がなされている。例えば、柑橘類に多く含まれるナリンジンやヘスペリジンなどのフラボノイドの働きについては、これまで多くの研究が行われており、抗酸化作用、循環器系疾患の予防、抗炎症、抗アレルギー、抗菌、抗ウイルス、血糖値の低下など多くの報告がある。
また、長年にわたり日常的に食品として摂取している植物抽出物を利用した血糖値上昇抑制剤、高レプチン血症予防・改善剤、高インスリン血症予防・改善剤、ペルオキシソーム増殖剤活性化受容体(PPAR)依存的遺伝子転写活性化剤、脂質代謝促進剤が知られている(特許文献1)。これは、コーヒー、リンゴ、ブドウ、たまねぎなどの植物から得られるクロロゲン酸類からなり、優れたPPAR依存的遺伝子転写活性化作用を有し、遺伝子の転写調節領域にPPR応答配列(PPRE)を有する遺伝子を活性化することにより、特に脂質代謝を活性化し、それにより種々の生活習慣病に対する効果を有するものである。
しかしながら、低コストで身近に手に入るものが少なく、より安全性に優れた身近な飲食品の開発が求められている。
On the other hand, food functions include a life-sustaining function (primary function) by food nutrients, a function in which food components appeal to living sensations (secondary function), and a function to adjust physical condition (tertiary function). Nutrition (primary function) and taste (secondary function) of food are well understood and recognized, but in recent years, tertiary functions such as food defense, physical condition rhythm control, disease prevention and recovery have attracted attention. Yes. Foods continue to be eaten every day, have a high potential for long-term effects on the body, and many researches and developments have been made on the functionality of foods. For example, many studies have been conducted on the action of flavonoids such as naringin and hesperidin, which are abundant in citrus fruits. Antioxidant activity, prevention of cardiovascular diseases, anti-inflammatory, antiallergic, antibacterial, antiviral There are many reports such as lowering of blood sugar level.
In addition, inhibitors of blood glucose level elevation, hyperleptinemia prevention / amelioration agent, hyperinsulinemia prevention / amelioration agent, peroxisome proliferator-activated receptor using plant extracts that have been ingested daily as food for many years (PPAR) -dependent gene transcription activators and lipid metabolism promoters are known (Patent Document 1). This gene consists of chlorogenic acids obtained from plants such as coffee, apple, grape, onion, etc., has an excellent PPAR-dependent gene transcription activation action, and has a PPR response element (PPRE) in the transcriptional regulatory region of the gene In particular, lipid metabolism is activated, thereby having an effect on various lifestyle-related diseases.
However, there are few things that are readily available at low cost, and there is a need for the development of familiar foods and drinks that are more safe.

また、柑橘類の果皮は、ジュース等の製造において多量に副生されるため、その用途として飼料に利用されていた。しかし、人に対しては官能的に苦いためそのままで食するには適さなかった。   In addition, citrus peel has been used as a feed for its use because it is by-produced in large quantities in the production of juice and the like. However, it is not suitable for eating as it is because it is sensually bitter to humans.

特開2003−34636公報JP 2003-34636 A

本発明の目的は、一度に多量の摂取が可能で、安全性に優れ、より効果の高い血糖値降下剤、便通改善剤を提供することにある。また、血糖値降下や便通改善の効果を有する飲食品を提供することにある。   An object of the present invention is to provide a hypoglycemic agent and a bowel movement improving agent that can be ingested in a large amount at once, is excellent in safety, and is more effective. Moreover, it is providing the food / beverage products which have the effect of a blood glucose level fall and a bowel movement improvement.

本発明を概説すれば、本発明の第1の発明は、柑橘類のアルベドを有効成分とする血糖値降下剤であり、本発明の第2の発明は、柑橘類のアルベドを有効成分とする便通改善剤であり、本発明の第3の発明は、該柑橘類がグレープフルーツである血糖値降下剤であり、本発明の第4の発明は、該柑橘類がグレープフルーツである便通改善剤であり、本発明の第5の発明は、該血糖値降下剤を含有している血糖値降下用の食品又は飲料であり、本発明の第6の発明は、該便通改善剤を含有している便通改善用の食品又は飲料である。   Briefly describing the present invention, the first invention of the present invention is a hypoglycemic agent containing citrus albedo as an active ingredient, and the second invention of the present invention is an improvement of bowel movement containing citrus albedo as an active ingredient. The third invention of the present invention is a hypoglycemic agent in which the citrus fruit is grapefruit, and the fourth invention of the present invention is a bowel movement improving agent in which the citrus fruit is grapefruit. A fifth invention is a food or beverage for reducing blood sugar level containing the blood glucose level lowering agent, and a sixth invention of the present invention is a food for improving bowel movement containing the bowel movement improving agent Or a beverage.

本発明者らは、前記従来技術の問題点を解決するために鋭意研究を行った結果、柑橘類に多量に存在するアルベドを摂食することにより、血糖値降下、便通改善、コレステロール低下の効果を有することを見出し、本発明の完成に至った。   As a result of diligent research to solve the problems of the prior art, the present inventors have eaten albedo that is present in large amounts in citrus fruits, thereby reducing blood glucose levels, improving bowel movements, and lowering cholesterol. As a result, the present invention has been completed.

本発明の柑橘類のアルベドを有効成分とする血糖値降下剤、便通改善剤は、一度に多量に摂取することができ、高い効果が得られるものである。また、通常では廃棄される果皮を利用しているため、安価で副作用の心配も少ないものである。   The blood glucose level lowering agent and the bowel movement improving agent containing the citrus albedo of the present invention as an active ingredient can be taken in a large amount at a time, and a high effect is obtained. Moreover, since the skin peeled normally is utilized, it is inexpensive and has little worry about side effects.

以下、本発明を具体的に説明する。
本発明における柑橘類は、アルベドが豊富に含まれている柑橘類であれば、その種類には特に限定はない。例えば、温州ミカン、ポンカン、シークワーシャー、スダチなどのミカン類、ネーブル、バレンシアなどのオレンジ類、夏ミカン、ハッサク、イヨカン、ダイダイなどの雑柑類、その他ブンタン、グレープフルーツ、レモン、ユズ類、キンカン類等があり、本発明では特にナリンジンなどのフラボノイドが多く存在するアルベドが豊富に含まれているグレープフルーツを用いることが好ましい。用いるグレープフルーツの品種に特に限定はなく、例えば、ダンカン、マーシュ、ルビーなどが挙げられる。
The present invention will be specifically described below.
The citrus fruits in the present invention are not particularly limited as long as they are citrus fruits rich in albedo. For example, mandarin oranges such as Wenzhou mandarin, Ponkan, Sikhwasher, Sudachi, oranges such as Navel and Valencia, summer mandarin oranges, Hassaku, Iyokan, Daidai and other citrus fruits, other Bungtan, grapefruit, lemon, yuzu, kumquats In the present invention, it is particularly preferable to use grapefruit rich in albedo containing a large amount of flavonoids such as naringin. There are no particular limitations on the grapefruit varieties used, and examples include Duncan, Marsh, and Ruby.

本発明で有効成分として使用するアルベドとは、柑橘類の中果皮である皮の白い部分を含んだものであり、ペクチンなどの水溶性食物繊維、ナリンジンやヘスペリジンなどを代表とするフラボノイドが多く含まれているものをいう。   The albedo used as an active ingredient in the present invention includes a white portion of the skin which is a citrus mesocarp and contains many water-soluble dietary fibers such as pectin, flavonoids such as naringin and hesperidin. Say what you are.

本発明で有効成分として使用するアルベドは、アルベドそれ自体を使用してもよいが、本発明で意図する薬理効果(血糖値降下又は便通改善)を無効としない程度にアルベドを加工して使用してもよい。例えば、(1)アルベドそれ自体、それに果皮がついたもの、全果磨砕したもの、(2)前記(1)のものを水、エタノール、酒類、梅酢、ハチミツ等に漬けたもの、(3)前記(1)のものをシロップ、ゼリー、ペースト、ジャム等にしたもの、(4)前記(1)のものを乾燥したもの、(5)前記(4)のものを粉砕して微粉、又は顆粒状に賦形したもの、(6)前記(1)、(4)、(5)等を水蒸気蒸留又は溶媒抽出して得られるもの、又は残渣、(7)前記(1)、(4)、(5)等を煎じたもの、(8)前記いずれのものでも、薬剤の形態に加工したものなどが挙げられる。薬剤の形態とする場合には、一般的に常用される剤型であればよく、例えば、粉末剤、錠剤、散剤、顆粒剤、カプセル剤、トローチ剤、シロップ剤、軟ゼラチンカプセル、ペースト等が挙げられる。   Albedo used as an active ingredient in the present invention may be albedo itself, but albedo is processed and used to the extent that the pharmacological effect (decrease in blood glucose level or improvement of bowel movement) intended in the present invention is not invalidated. May be. For example, (1) Albedo itself, with skin attached to it, whole fruit ground, (2) (1), soaked in water, ethanol, liquor, plum vinegar, honey, etc. (3 ) (1) made into syrup, jelly, paste, jam, etc., (4) dried from (1), (5) pulverized from (4), or fine powder, (6) those obtained by steam distillation or solvent extraction of (1), (4), (5) etc., or residues, (7) (1), (4) , (5), etc., and (8) any of the above, processed into a pharmaceutical form. In the case of a pharmaceutical form, it may be any commonly used dosage form, such as powders, tablets, powders, granules, capsules, troches, syrups, soft gelatin capsules, pastes, etc. Can be mentioned.

本発明で有効成分として使用するアルベドは、そのまま摂取することもできるし、食品又は飲料に加えて摂取することもできる。食品又は飲料に加える場合、使用する食品又は飲料の種類に限定はない。食品としては、例えば、パン、ケーキ、ドーナツ、チョコレート、キャンディー、ビスケット、ゼリー、ヨーグルト、まんじゅう等の菓子類、ソース、ドレッシング等の調味料類、惣菜類、加工食品類等への使用が挙げられる。惣菜は穀類、イモ類、種実類、豆類、魚介類、獣鳥鯨肉類、卵類、野菜類、キノコ類、藻類及びこれらの混合物を調理したものであり、焼く、煎る、炒める、揚げる、蒸す、ゆでる、煮る等、いずれの方法においても使用できる。飲料としては、例えば、コーヒー、紅茶、緑茶、中国茶、ココア等の嗜好飲料類、清涼飲料、リンゴ、オレンジ、グレープフルーツ、ブドウ等の果汁ジュース等の飲料類、リキュール等の酒類等への使用が挙げられる。   The albedo used as an active ingredient in the present invention can be taken as it is or in addition to food or beverage. When added to food or beverage, the type of food or beverage used is not limited. Examples of the food include use for confectionery such as bread, cake, donut, chocolate, candy, biscuits, jelly, yogurt and manju, seasonings such as sauce and dressing, side dishes, processed foods and the like. . Prepared meals are cereals, potatoes, seeds, beans, seafood, animal fowls, eggs, vegetables, mushrooms, algae, and mixtures thereof, baked, roasted, fried, fried, steamed , Boiled, boiled and so on. Examples of beverages include beverages such as coffee, tea, green tea, Chinese tea, cocoa and other favorite beverages, soft drinks, juices such as apples, oranges, grapefruits and grapes, and liquors such as liqueurs. Can be mentioned.

本発明における柑橘類のアルベドを有効成分とする血糖値降下剤、便通改善剤の摂取量は、年齢、体重、性別等の種々の要因によって異なるが、例えば、グレープフルーツのアルベドを60℃、24時間通風乾燥し、60メッシュパスで得られた粉末では、成人(体重60kg)1日当り2〜3gが好ましく、1日1回〜数回に分けて摂取することが好ましい。摂取期間としては、3週を超えての期間が好ましく、4週以上が特に好ましい。なお、急性毒性については、天然物由来のものであり安全なものである。マウスを用いてのLD50は、2g/kg以上である。 The intake of a hypoglycemic agent and a bowel movement improving agent containing citrus albedo as an active ingredient in the present invention varies depending on various factors such as age, weight, and sex. For example, grapefruit albedo is ventilated at 60 ° C. for 24 hours. The dry powder obtained by 60 mesh pass is preferably 2 to 3 g per day for an adult (body weight 60 kg), preferably taken once to several times a day. As the intake period, a period exceeding 3 weeks is preferable, and 4 weeks or more is particularly preferable. As for acute toxicity, it is derived from natural products and is safe. The LD 50 using a mouse is 2 g / kg or more.

以下、実施例によって本発明を更に具体的に説明するが、本発明がこれらの実施例に限定されるものではない。   EXAMPLES Hereinafter, the present invention will be described more specifically with reference to examples, but the present invention is not limited to these examples.

グレープフルーツを用い、アルベド粉末を調製した。まず、グレープフルーツ生果400gを洗浄し、トリミング(剥皮)してアルベド30gを得、60℃、24時間の温風乾燥を行い、アルベド乾燥物を7.4g得た。それを微粉砕し、篩にかけて60メッシュパスのアルベド粉末を調製した。
空腹時の血糖値が110mg/dl以上で、BMI指数が19〜30程度の健康な成人男女13名に、各々、調製したグレープフルーツのアルベド粉末2gを、4週間にわたって毎日昼食若しくは夕食後にコップ1杯の水に溶解して摂取させた。検査前日は、午後9時以降の飲食を禁止し、上腕屈側部の静脈より採血した。検査項目は生化学検査(血糖値、HbAc、フルクトサミン、グリコアルブミン、インスリン、総タンパク、総コレステロール、HDL−C、中性脂肪、GOT、GPT、LDH、γ−GTP、クレアチニン、尿素窒素、尿酸、アルブミン、Na、K、Cl)、血液一般検査(白血球数、赤血球数、ヘモグロビン、ヘマトクリット、血小板数)、尿検査(pH、タンパク、糖、潜血)、その他(身長、体重、血圧、脈拍数)について行った。生化学検査の結果及び体重を表1に示す。
Albedo powder was prepared using grapefruit. First, 400 g of fresh grapefruit fruit was washed and trimmed (peeled) to obtain 30 g of albedo, followed by hot air drying at 60 ° C. for 24 hours to obtain 7.4 g of dried albedo. It was finely pulverized and sieved to prepare a 60 mesh pass albedo powder.
Thirteen healthy adult men and women with a fasting blood glucose level of 110 mg / dl or higher and a BMI index of about 19-30, each with 2 grams of prepared grapefruit albedo powder after a daily lunch or dinner for 4 weeks And dissolved in water. On the day before the examination, eating and drinking after 9 pm was prohibited, and blood was collected from the vein on the side of the flexor arm. Test items are biochemical tests (blood glucose level, HbA 1 c, fructosamine, glycoalbumin, insulin, total protein, total cholesterol, HDL-C, neutral fat, GOT, GPT, LDH, γ-GTP, creatinine, urea nitrogen, Uric acid, albumin, Na, K, Cl), general blood test (white blood cell count, red blood cell count, hemoglobin, hematocrit, platelet count), urine test (pH, protein, sugar, occult blood), others (height, weight, blood pressure, pulse) Number). Results of biochemical tests and body weight are shown in Table 1.

Figure 2005272456
Figure 2005272456

表1の結果より、被験者13名のうち10名で血糖値が低下し、有意な低下(P<0.01)が認められたことから、グレープフルーツのアルベドには血糖値降下作用があることが確認できた。   From the results in Table 1, 10 out of 13 subjects showed a decrease in blood glucose level, and a significant decrease (P <0.01) was observed. Therefore, grapefruit albedo may have a blood glucose level lowering effect. It could be confirmed.

実施例1と同様に、調製したグレープフルーツのアルベド粉末を、健常者13名に、1日2gを4週間にわたって毎日昼食若しくは夕食後にコップ1杯の水に溶解して摂取させた。摂取期間中、排便の回数や便の調子など日誌を記入させた。排便の回数結果を表2に示す。   In the same manner as in Example 1, the prepared grapefruit albedo powder was ingested by 13 healthy subjects by dissolving 2 g per day in a glass of water after lunch or dinner every day for 4 weeks. During the ingestion period, a diary was recorded on the number of defecations and stool tone. Table 2 shows the results of the number of defecations.

Figure 2005272456
Figure 2005272456

表2の結果より、排便回数が2週目で有意に増加しており、便通改善効果を確認できた。   From the results in Table 2, the number of bowel movements increased significantly in the second week, and the effect of improving bowel movement was confirmed.

実施例1で調製したグレープフルーツのアルベド粉末を用い、表3の仕込配合表に基づいて原材料を調合し、95℃で殺菌した後、190gのスチール缶に充填し、グレープフルーツ飲料を製造した。仕込配合を表3に示す。   Using the grapefruit albedo powder prepared in Example 1, the raw materials were prepared based on the preparation recipe in Table 3, sterilized at 95 ° C., and then filled into a 190 g steel can to produce a grapefruit beverage. The charging composition is shown in Table 3.

Figure 2005272456
Figure 2005272456

本発明1、本発明2を毎日190g喫食したところ、血糖値降下作用も認められ、また便の通じもよくなった。なお、190g中には、本発明1では2.2g相当のアルベド粉末が含まれ、本発明2では3.0g相当のアルベド粉末が含まれる。   As a result of eating 190 g of the present invention 1 and 2 every day, a blood glucose level lowering action was observed, and stool communication was also improved. In 190 g, the present invention 1 includes 2.2 g of albedo powder, and the present invention 2 includes 3.0 g of albedo powder.

実施例1で調製したグレープフルーツのアルベド粉末920g、結晶セルロース50g、ショ糖脂肪酸エステル30gを配合して打錠し、グレープフルーツアルベドの錠剤(本発明3)を製造した。錠剤1粒は200mgとする。打錠条件は1kg/cm〜2kg/cmである。 Grapefruit albedo powder prepared in Example 1 (920 g), crystalline cellulose (50 g), and sucrose fatty acid ester (30 g) were blended and compressed to produce grapefruit albedo tablets (present invention 3). One tablet is 200 mg. Tableting conditions are 1kg / cm 2 ~2kg / cm 2 .

本発明3を毎日、1回4〜5錠で1日2〜3回(1日およそ11錠)を喫食したところ、血糖値降下作用も認められ、また便の通じもよくなった。   When the present invention 3 was eaten 4 to 5 tablets once a day and 2 to 3 times a day (approximately 11 tablets a day), a blood glucose level lowering action was also observed, and stool communication was also improved.

グレープフルーツを洗浄し、外果皮をトリミング(剥皮)してアルベドを残した状態とする。同時に異物、腐れ果を除去する。次に98℃の沸騰水中に浸して酵素を失活させ、その後、低温の冷気を高速で果実に流す送風凍結法で急速冷凍する。冷凍したグレープフルーツをハンマークラッシャーで粗破砕した後、スーパーマスコロイダーを用い、そのクリアランスを200μmに調整して磨砕する。磨砕後、高圧ホモゲナイザーで均質化し、グレープフルーツ磨砕物を得た。得られた磨砕物1kgには、乾燥物換算で18.5gのアルベドを含有する。
このグレープフルーツ磨砕物を主原料に用い、表4の仕込配合表に基づいて原材料を調合し、95℃で殺菌した後、2リットルのペットボトルに充填し、グレープフルーツの50w/w%果汁入り飲料(本発明4)を製造した。仕込配合表を表4に示す。
Grapefruit is washed and the outer skin is trimmed (peeled) to leave an albedo. At the same time, remove foreign matter and rot. Next, the enzyme is deactivated by dipping in boiling water at 98 ° C., and then rapidly frozen by a blow freezing method in which low-temperature cold air is passed through the fruit at high speed. The frozen grapefruit is roughly crushed with a hammer crusher and then ground using a super mass collider with a clearance adjusted to 200 μm. After grinding, the mixture was homogenized with a high-pressure homogenizer to obtain a grapefruit ground product. 1 kg of the obtained ground product contains 18.5 g of albedo in terms of dry matter.
This grapefruit ground product is used as the main ingredient, and the raw materials are prepared based on the preparation table in Table 4, sterilized at 95 ° C, filled into 2 liter PET bottles, and a grapefruit 50w / w% fruit juice beverage ( Invention 4) was prepared. The charging recipe is shown in Table 4.

Figure 2005272456
Figure 2005272456

本発明4を毎日220g喫食したところ、血糖値降下作用も認められ、便の通じもよくなった。なお、220g中には、本発明4では2.0g相当のアルベド粉末が含まれる。   When 220 g of the present invention 4 was eaten every day, a blood glucose level lowering action was also observed, and stool communication was improved. In addition, in this invention 4, the albedo powder equivalent to 2.0g is contained in this invention 4.

糖尿病マウス(C57BLKS/J Iar−+Leprdb/Leprdb)を用いて、実施例1と同様の方法で調製したグレープフルーツのアルベド粉末の血糖値降下作用について検討を行った。
7週齢の糖尿病マウス(C57BLKS/J Iar−+Leprdb/Leprdb)の雄21匹を用い、一週間の馴化飼育後、採血し、血糖値により1群7匹ずつ3群に割り付けた。
被験物質(グレープフルーツのアルベド粉末)を通常食(粉末飼料CE−2、日本クレア株式会社製)に各投与量を混ぜ、自由摂取を4週間行った。その間の飲料水は公共水道水を自由摂取させた。試験区としては、1群を7匹として、対照群、低用量群、高用量群の3群とした。
対照群には、グレープフルーツのアルベド粉末を含まない通常食のみを飼料として与えた。低用量群には、グレープフルーツのアルベド粉末を通常食に2%混餌したものを、高用量群には5%混餌したものをそれぞれ飼料として与えた。
投与開始後、体重測定は週1回行い、採血は投与開始時(0日目)、投与開始2週間後、及び投与終了時(投与開始4週間後)の計3回行い、血糖値の測定を行った。
飼育期間中の血糖値の平均値を表5に示す。
Using diabetic mice (C57BLKS / J Iar− + Lepr db / Lepr db ), the hypoglycemic effect of grapefruit albedo powder prepared in the same manner as in Example 1 was examined.
Seventeen-week-old diabetic mice (C57BLKS / J Iar− + Lepr db / Lepr db ) were used for 21 weeks of acclimatization, blood was collected, and 7 groups were assigned to 3 groups according to blood glucose level.
Each dose of the test substance (grapefruit albedo powder) was mixed with a normal diet (powder feed CE-2, manufactured by CLEA Japan, Inc.) and allowed to freely ingest for 4 weeks. In the meantime, drinking water was freely consumed by public tap water. As the test group, one group consisted of 7 animals, and the control group, the low dose group, and the high dose group consisted of 3 groups.
The control group was fed only a normal diet without grapefruit albedo powder. The low dose group was fed with 2% grapefruit albedo powder as a normal diet, and the high dose group was fed with 5% diet as a feed.
After the start of administration, body weight is measured once a week, and blood sampling is performed 3 times in total at the start of administration (day 0), 2 weeks after the start of administration, and at the end of the administration (after 4 weeks of administration) to measure blood glucose levels Went.
Table 5 shows the average blood glucose level during the breeding period.

Figure 2005272456
Figure 2005272456

表5の結果より、通常食のみを与える対照群とグレープフルーツのアルベド粉末投与群(低用量群、高用量群)を比較すると、投与開始4週間後に用量依存的な血糖値の減少が観察された。
対照群では、投与開始時(0日目)の170.4mg/dlから、投与開始4週間後には255.3mg/dlと上昇傾向にあったのに対し、低用量群では213.4mg/dl、高用量群では183.4mg/dlとなり、グレープフルーツのアルベド粉末には血糖値降下作用のあることが確認された。
投与開始4週間後という非常に短期間において、高い血糖値降下作用を示すものであった。
From the results shown in Table 5, a dose-dependent decrease in blood glucose level was observed 4 weeks after the start of administration when comparing the control group given only the normal diet with the grapefruit albedo powder administration group (low dose group, high dose group). .
In the control group, it increased from 170.4 mg / dl at the start of administration (day 0) to 255.3 mg / dl 4 weeks after the start of administration, whereas in the low dose group, 213.4 mg / dl. In the high dose group, it was 183.4 mg / dl, and it was confirmed that the grapefruit albedo powder has a blood glucose lowering effect.
In a very short period of 4 weeks after the start of administration, it showed a high blood glucose level lowering effect.

本発明の柑橘類のアルベドを有効成分とする血糖値降下剤、便通改善剤は、そのまま摂取することもできるし、該血糖値降下剤、便通改善剤を食品又は飲料に添加することもできるので有用である。また、一度に多量の摂取が可能であり、安全性に優れ、より効果の高い血糖値降下、便通改善が期待できる。また、この血糖値降下剤、便通改善剤を毎日摂取することにより、食習慣、運動習慣、休養、喫煙、飲酒等の食生活などに起因する生活習慣病の症状軽減又は発症予防が期待できる。また、通常廃棄されるアルベドを有効成分として利用することは、産業上、天然物廃棄物利用の面からも有用な発明である。
The hypoglycemic agent and the bowel movement improving agent comprising the citrus albedo of the present invention as an active ingredient can be ingested as they are, and are useful because the hypoglycemic agent and the bowel movement improving agent can be added to foods or beverages. It is. In addition, a large amount can be ingested at one time, which is excellent in safety and can be expected to lower blood glucose level and improve bowel movement more effectively. In addition, daily intake of this hypoglycemic agent and bowel movement-improving agent can be expected to reduce or prevent symptoms of lifestyle-related diseases caused by dietary habits, exercise habits, rest, smoking, drinking and other eating habits. In addition, the use of albedo, which is normally discarded, as an active ingredient is an industrially useful invention from the viewpoint of utilizing natural product waste.

Claims (6)

柑橘類のアルベドを有効成分とすることを特徴とする血糖値降下剤。   A hypoglycemic agent comprising citrus albedo as an active ingredient. 柑橘類のアルベドを有効成分とすることを特徴とする便通改善剤。   A bowel movement improving agent comprising a citrus albedo as an active ingredient. 柑橘類がグレープフルーツであることを特徴とする請求項1記載の血糖値降下剤。   2. The hypoglycemic agent according to claim 1, wherein the citrus fruit is grapefruit. 柑橘類がグレープフルーツであることを特徴とする請求項2記載の便通改善剤。   The stool is a grapefruit, The bowel movement improving agent of Claim 2 characterized by the above-mentioned. 請求項1又は3記載の血糖値降下剤を含有していることを特徴とする血糖値降下用の食品又は飲料。   A food or beverage for lowering blood glucose, comprising the blood glucose lowering agent according to claim 1 or 3. 請求項2又は4記載の便通改善剤を含有していることを特徴とする便通改善用の食品又は飲料。   A food or beverage for improving bowel movements comprising the bowel movement improving agent according to claim 2 or 4.
JP2005048803A 2004-02-24 2005-02-24 Hypoglycemic agent or cathartic agent Pending JP2005272456A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2005048803A JP2005272456A (en) 2004-02-24 2005-02-24 Hypoglycemic agent or cathartic agent

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004047175 2004-02-24
JP2005048803A JP2005272456A (en) 2004-02-24 2005-02-24 Hypoglycemic agent or cathartic agent

Publications (1)

Publication Number Publication Date
JP2005272456A true JP2005272456A (en) 2005-10-06

Family

ID=35172493

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2005048803A Pending JP2005272456A (en) 2004-02-24 2005-02-24 Hypoglycemic agent or cathartic agent

Country Status (1)

Country Link
JP (1) JP2005272456A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006077975A1 (en) * 2005-01-21 2006-07-27 Arkray, Inc. Metabolic syndrome-improving agent and medicine, supplement, functional food and food additive containing the same
JP2015036369A (en) * 2013-08-13 2015-02-23 国立大学法人愛媛大学 Oral composition for antiallergic
JP2016169219A (en) * 2016-04-22 2016-09-23 国立大学法人愛媛大学 Oral composition for antiallergic

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58165754A (en) * 1982-03-25 1983-09-30 Nippon Kajitsu Kogyo Kk Method for making endocarp of citrus fruit edible
JPS6349055A (en) * 1986-08-15 1988-03-01 Koki Bussan Kk Preparation of edible fiber raw material
JP2002300866A (en) * 2000-10-27 2002-10-15 Takara Holdings Inc Fruit beverage and method for producing the same
JP2003507486A (en) * 1999-08-19 2003-02-25 コリア リサーチ インスティチュート オブ バイオサイエンス アンド バイオテクノロジー Flavonoids derived from citrus peel as inhibitors of collagen-induced platelet aggregation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58165754A (en) * 1982-03-25 1983-09-30 Nippon Kajitsu Kogyo Kk Method for making endocarp of citrus fruit edible
JPS6349055A (en) * 1986-08-15 1988-03-01 Koki Bussan Kk Preparation of edible fiber raw material
JP2003507486A (en) * 1999-08-19 2003-02-25 コリア リサーチ インスティチュート オブ バイオサイエンス アンド バイオテクノロジー Flavonoids derived from citrus peel as inhibitors of collagen-induced platelet aggregation
JP2002300866A (en) * 2000-10-27 2002-10-15 Takara Holdings Inc Fruit beverage and method for producing the same

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006077975A1 (en) * 2005-01-21 2006-07-27 Arkray, Inc. Metabolic syndrome-improving agent and medicine, supplement, functional food and food additive containing the same
US8257755B2 (en) 2005-01-21 2012-09-04 Arkray, Inc. Metabolic syndrome-improving agent and medicine, supplement, functional food and food additive containing the same
JP2015036369A (en) * 2013-08-13 2015-02-23 国立大学法人愛媛大学 Oral composition for antiallergic
JP2016169219A (en) * 2016-04-22 2016-09-23 国立大学法人愛媛大学 Oral composition for antiallergic

Similar Documents

Publication Publication Date Title
Nasar‐Abbas et al. Carob kibble: A bioactive‐rich food ingredient
JP5109117B2 (en) Sudachi-derived composition, and pharmaceutical composition, health food and drink and supplement containing the composition
KR101102578B1 (en) Method producing functional vinegar picked egg and functional vinegar picked egg produced by the same method
JP3768795B2 (en) Xanthine oxidase inhibitor
KR100549193B1 (en) Foods comprising ginseng and powders or extracts of plants comprising polyphenol or bioflavonoid for suppressing the fatness
CN106999532A (en) The enhancing of Motor execution ability and physical enhancement composition containing composite extract
KR20160141027A (en) Phamaceutical composition or healthy food comprising water extracts from Pleurotus eryngii var. ferulea (Pf.). for treating or preventing metabolic disorder
JP2006036787A (en) Xanthine oxidase inhibitor
KR102112599B1 (en) Anti-obesity composition comprising Punica granatum and Citrus junos extract as effective component
JP2005272456A (en) Hypoglycemic agent or cathartic agent
EP1962826B1 (en) Method for weight reduction
KR101952643B1 (en) Preparation method of grain noodle
KR100503208B1 (en) Diet-food composition
JP2001299273A (en) Health food and health drink
Abad AlegrÃa et al. The health and nutritional virtues of artichokes-from folklore to science
KR100615981B1 (en) Yogurt composition for the control of a blood glucose
JP6273440B2 (en) GLP-1 production promoter, DPPIV inhibitor and glucose absorption inhibitor
KR101811210B1 (en) Composition for treatment, improvement or prevention of Diabetes comprising extract of fruit of Sorbus commixta as an effective component
JP2006193501A (en) Adiponectin regulating agent and food, drink, food additive and medicine containing the same
KR101572580B1 (en) Herbal medicine composition having improved adaptability of taking medicine and preparation method thereof
KR101709564B1 (en) Method for procucing Moju containing purple sweet potato and barley
KR102485676B1 (en) A composition for improving, preventing and treating of obesity comprising Ulva pertusa Kjellman extracts
JP3476835B2 (en) Yacon / oolong blended food
KR102358168B1 (en) Ginseng powder with increased ginsenoside Rh1 and polyphenol contents and method for manufacturing the ginseng powder
KR20130082249A (en) Composition for preventing or improving the metabolic syndrome containing parthenocissus tricuspidata extract

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110516

RD07 Notification of extinguishment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7427

Effective date: 20110624

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110715

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110912

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120402